Boston Scientific (BSX) agrees to acquire privately held Vessix Vascular for $125M up front and...


Boston Scientific (BSX) agrees to acquire privately held Vessix Vascular for $125M up front and milestone payments of up to $300M in 2013-2017. Vessix develops the Vascular V2 Renal Denervation System for the treatment of hypertension, which BSX expects will "be a multi-billion dollar market by 2020."

From other sites
Comments (1)
  • Amod Saul
    , contributor
    Comments (111) | Send Message
     
    $300M for Vessix is a good buy, the RDN market is hot right now: http://bit.ly/SRnbco , with many medical technology heavy weights scrambling for share and very few RDN technology start-ups available for sale.
    9 Nov 2012, 01:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs